Welcome to our dedicated page for Cartesian news (Ticker: RNAC), a resource for investors and traders seeking the latest updates and insights on Cartesian stock.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is a clinical-stage biotechnology company that describes itself as pioneering cell therapy for autoimmune diseases. Its news flow centers on the development of its lead CAR-T candidate, Descartes-08, and its next-generation CAR-T program, Descartes-15. Company press releases highlight clinical trial milestones, regulatory designations, financial updates and corporate governance changes that are relevant for followers of RNAC news.
A major focus of Cartesian’s news is the Phase 3 AURORA trial of Descartes-08 in generalized myasthenia gravis (MG). Updates describe enrollment progress, prior Phase 2b data in MG, and the outpatient, no-preconditioning chemotherapy design of the AURORA trial. Additional news covers Descartes-08 development in systemic lupus erythematosus (SLE), including initial Phase 2 data, and the planned and ongoing expansion into myositis through a randomized, double-blind, placebo-controlled Phase 2 trial using a seamless adaptive design.
Cartesian also issues releases on pediatric autoimmune programs, such as a planned Phase 2 pediatric basket trial and the Phase 1/2 HELIOS pediatric trial, building on Rare Pediatric Disease Designation for Descartes-08 in juvenile dermatomyositis. Other recurring RNAC news items include quarterly financial results with commentary on cash runway and research and development spending, employment inducement grants under its inducement plan, and board and executive changes documented in Form 8-K filings, such as the appointment of new directors and officers.
Investors and observers tracking RNAC news can expect coverage of clinical data readouts, trial initiations or pauses, regulatory designations, strategic prioritization of indications, and corporate governance developments. Bookmarking this page provides a centralized view of Cartesian’s press releases and related updates as the company advances Descartes-08 and Descartes-15 through clinical development in autoimmune disease and multiple myeloma.
Cartesian Therapeutics (NASDAQ: RNAC) reported Q3 2025 results and clinical updates on Nov 6, 2025. The company reported $145.1 million in cash, cash equivalents and restricted cash as of Sept 30, 2025, which it expects will support operations into mid-2027, including completion of the Phase 3 AURORA trial.
Clinical highlights: enrollment is on track in the randomized Phase 3 AURORA trial of Descartes-08 in acetylcholine receptor antibody-positive myasthenia gravis (~100 participants; primary endpoint: ≥3-point MG-ADL improvement at Month 4), preliminary Phase 2 Descartes-08 SLE data expected by year-end, and a pediatric basket Phase 2 trial initiation expected by year-end; FDA granted Rare Pediatric Disease Designation for Descartes-08 in juvenile dermatomyositis. Descartes-15 Phase 1 in multiple myeloma remains ongoing.
Financials: R&D $13.8M, G&A $7.7M for Q3 2025; net loss $35.9M, or $1.38 per share, vs. net loss $24.2M, or $1.13 per share in Q3 2024.
Cartesian Therapeutics (NASDAQ: RNAC) announced inducement stock-option awards to two new employees dated Oct 27, 2025 and Oct 29, 2025. One option covers 50,000 shares at an exercise price of $8.85 (closing price on Oct 27, 2025); the other covers 2,650 shares at an exercise price of $8.20 (closing price on Oct 29, 2025).
Both grants were approved by the board under the Amended and Restated 2018 Employment Inducement Incentive Award Plan, vest 25% after one year then in three equal annual installments (fully vested in 2029), and carry a 10-year term. Grants were made under Nasdaq Rule 5635(c)(4) as inducements to employment.
Cartesian Therapeutics (NASDAQ: RNAC) announced that Carsten Brunn, Ph.D., currently President and CEO, was named Chairman of the Board effective October 29, 2025.
Dr. Brunn succeeds Carrie S. Cox, who is stepping down to focus on other responsibilities, including a recent appointment as Executive Chair of another publicly traded company. In connection with the change, Patrick Zenner, M.B.A. was named Lead Independent Director.
The company highlighted progress advancing Descartes-08 toward its first planned regulatory submission and referenced the board leadership transition as part of its corporate governance updates.
Cartesian Therapeutics (NASDAQ: RNAC) announced an employment inducement grant for one new employee on Oct 2, 2025. The company issued an option for 9,700 shares with an exercise price of $10.34 (Nasdaq close on grant date). The option was approved by the board and granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement award.
The option vests 25% on Oct 2, 2026, then in three equal annual installments, becoming fully vested on Oct 2, 2029, and carries a 10-year term.
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on cell therapy for autoimmune diseases, has announced its participation in three major healthcare investor conferences in September 2025.
The company will participate in the Cantor Global Healthcare Conference on September 4, the Morgan Stanley Healthcare Conference on September 9, and the H.C. Wainwright Global Investment Conference on September 10. All presentations will be available via webcast on the company's website.
Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 2025 financial results and provided key pipeline updates. The company has initiated its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis, with the first participant enrolled in May 2025. The trial will evaluate the therapy versus placebo in approximately 100 participants.
The company maintains a strong financial position with $162.1 million in cash and equivalents as of June 30, 2025, expected to fund operations into mid-2027. Q2 2025 saw a net income of $15.9 million ($0.51 per share). Cartesian anticipates preliminary data from its Phase 2 trial of Descartes-08 in systemic lupus erythematosus and plans to initiate a pediatric basket trial in select autoimmune indications in 2H25.
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focused on cell therapy for autoimmune diseases, has granted employment inducement awards to two new employees. The company issued stock options to purchase 5,750 shares at an exercise price of $12.48 per share on August 4, 2025.
The options were granted under the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan with a four-year vesting schedule. The initial 25% vests on August 4, 2026, followed by three equal annual installments, becoming fully vested by August 4, 2029. The options have a ten-year term and were granted under Nasdaq Rule 5635(c)(4).